SCHEMBL6319784

SCHEMBL6319784

COc1cccc(-c2cccc3c2/C(=C/c2[nH]c(C)c(C(=O)N4CCN(C)CC4)c2C)C(=O)N3)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.55
AURKB Q96GD4 5/20 0.55
MET P08581 5/20 0.51
KDR P35968 11/20 0.51
FGFR1 P11362 7/20 0.51
MEN1 O00255 1/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
RECQL P46063 1/20 0.51
KMT2A Q03164 1/20 0.51
PTK2B Q14289 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
PDGFRB P09619 8/20 0.48
EGFR P00533 2/20 0.48
FLT1 P17948 1/20 0.47
RET P07949 2/20 0.44
ALK Q9UM73 2/20 0.44
ABL1 P00519 1/20 0.44
LRRK2 Q5S007 2/20 0.43
KIT P10721 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319792 1.00 FLT3 (0.55) FLT3AURKBMETKDRFGFR1
SCHEMBL6321383 0.92 FLT3 (0.55) FLT3AURKBMETKDRFGFR1
SCHEMBL6321388 0.92 FLT3 (0.55) FLT3AURKBMETKDRFGFR1
SCHEMBL6322336 0.91 KDR (0.49) FLT3AURKBMETKDRFGFR1
SCHEMBL6323687 0.89 MET (0.56) FLT3AURKBMETKDRFGFR1
SCHEMBL6323692 0.89 MET (0.56) FLT3AURKBMETKDRFGFR1
SCHEMBL6328542 0.89 KDR (0.57) FLT3AURKBMETKDRFGFR1
SCHEMBL6323994 0.89 MET (0.52) FLT3AURKBMETKDRFGFR1
SCHEMBL6328538 0.89 KDR (0.57) FLT3AURKBMETKDRFGFR1
SCHEMBL6321870 0.89 KDR (0.62) FLT3AURKBMETKDRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 FLT3 596/4885AURKB 325/4885MET 501/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 FLT3 596/4885AURKB 325/4885MET 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.